This study examined the hypothesis that curcumin supplementation decreases blood levels of IL-6, MCP-1, TNF-alpha, hyperglycemia, and oxidative stress by using a cell-culture model and a diabetic rat model. U937 monocytes were cultured with control (7 mM) and high glucose (35 mM) in the absence or presence of curcumin (0.01-1 microM) at 37 degrees C for 24 h. Diabetes was induced in Sprague-Dawley rats by injection of streptozotocin (STZ) (i.p., 65 mg/kg BW). Control buffer, olive oil, or curcumin (100 mg/kg BW) supplementation was administered by gavage daily for 7 weeks. Blood was collected by heart puncture with light anesthesia. Results show that the effect of high glucose on lipid peroxidation, IL-6, IL-8, MCP-1, and TNF-alpha secretion was inhibited by curcumin in cultured monocytes. In the rat model, diabetes caused a significant increase in blood levels of IL-6, MCP-1, TNF-alpha, glucose, HbA(1), and oxidative stress, which was significantly decreased in curcumin-supplemented rats. Thus, curcumin can decrease markers of vascular inflammation and oxidative stress levels in both a cell-culture model and in the blood of diabetic rats. This suggests that curcumin supplementation can reduce glycemia and the risk of vascular inflammation in diabetes.

SUMMARYChromium (Cr 3+ ) supplementation facilitate normal protein, fat and carbohydrate metabolism, and is widely used by public in many countries. This study examined the effect of chromium niacinate (Cr-N) or chromium picolinate (Cr-P) supplementation on lipid peroxidation (LP), TNF-α, IL-6, CRP, glycosylated hemoglobin (HbA 1 ), cholesterol and triglycerides (TG) in diabetic rats. Diabetes (D) was induced in Sprague Dawley rats by streptozotocin (STZ) (ip, 65 mg/kg BW). Control buffer, Cr-N or Cr-P (400 µg Cr/Kg BW) was administered by gavages daily for 7 wks. Blood was collected by heart puncture using light anesthesia. Diabetes caused a significant increase in blood levels of TNF-α, IL-6, glucose, HbA 1 , cholesterol, TG and LP. Compared with D, Cr-N supplementation lowered the blood levels of TNF-α (p=0.04), IL-6 (p=0.02), CRP (p=0.02) LP (p=0.01), HbA 1 (p=0.02), TG (p=0.04) and cholesterol (p=0.04). Compared with D, Cr-P supplementation showed a decrease in TNF-α (p=0.02), IL-6 (p=0.02) and LP (p=0.01). Chromium niacinate lowers blood levels of pro-inflammatory cytokines (TNF-α, IL-6, CRP), oxidative stress and lipids levels in diabetic rats, and appears to be more effective form of Cr 3+ -supplementation. This study suggests that Cr 3+ -supplementation can lower risk of vascular inflammation in diabetes.

This study examined the hypothesis that L-cysteine supplementation can lower insulin resistance, glycemia, oxidative stress and markers of vascular inflammation in type 2 diabetes using zucker diabetic rats (ZDF) rats as a model. Starting at age of 6 wks, ZDF rats were supplemented orally (daily gavage, 8 wks) with saline-placebo (D) or L-cysteine (LC, 1mg/KgBW) and fed a high calorie diet. 6 weeks age rats without any supplementation were considered baseline (BL) rats. D rats showed elevated fasting blood glucose, GHb, CRP, and MCP-1 when compared with BL in which there was no onset of diabetes. LC supplementation significantly lowered blood levels of glucose (18%, p=0.05), GHb (8%, p=0.02), CRP (23%, p=0.02), MCP-1 (32%, p=0.01) and insulin resistance (25%) compared with levels seen in saline-supplemented D. There was a decrease in plasma protein oxidation levels (p<0.01); however, GSH levels were similar in LC and D groups. While LC did not change blood hematocrit or levels of transaminases, it did lower alkaline phosphatase (29%, p=0.01) levels in comparison to D. Western blotting analyses of liver showed increased activation of NFkB and Akt (50% pNFkB and 20% pAkt) in D compared with BL. LC supplementation inhibited these effects (17% pAkt, 18% pNFkB). This is the first report showing L-cysteine supplementation can lower glycemia and markers of vascular inflammation in diabetes apparently mediated by preventing NFkB activation in a diabetic animal model.

Aim Chromium and cysteine supplementation can improve glucose metabolism in animal studies. This study examined the hypothesis that a cysteinate complex of chromium is significantly beneficial than either of them in lowering blood glucose and vascular inflammation markers in ZDF rats. Methods Starting at the age of 6 wks, ZDF rats were supplemented orally (daily gavages for 8 more wks) with saline-placebo (D) or chromium (400µg Cr/KgBW) as chromium-dinicocysteinate (CDNC), chromium-dinicotinate (CDN), or chromium-picolinate (CP) or equimolar L-cysteine (LC, img/Kg BW), and fed Purina 5008 diet for 8 wks. ZDF rats of 6 wks age before any supplementations and onset of diabetes were considered as baseline (BL). Results D rats showed elevated levels of fasting blood glucose, HbA1, CRP, MCP-1, ICAM-1 and oxidative stress (LP) and lower adiponectin and vitamin C, when compared to BL rats. In comparison to D group, CDNC group had significantly lower blood glucose, HbA1, CRP, MCP-1, ICAM-1 and LP and increased vitamin C and adiponectin levels. CDN, CP or LC showed significantly less or no effect on these biomarkers. Only CDNC lowered blood creatinine levels in comparison to D. While CDN and CP had no effect, activation of NFkB, Akt and GLUT-2 levels were decreased, IRS-1 activation increased in livers of CDNC-rats. CDNC effect on glycemia, NFkB, Akt and IRS-1 in liver was significantly greater compared with LC. Blood chromium levels did not differ between Cr-groups. Exogenous vitamin C supplementation significantly inhibited MCP-1 secretion in U937 monocytes cultured in high-glucose-medium. Conclusions CDNC is a potent hypoglycemic compound with anti-inflammatory activity apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkB, Akt, and Glut-2 and increased IRS-1 activation in livers of type 2 diabetic rats.

Elevated blood levels of the proinflammatory cytokines interleukin-6 (IL-6), interleukin-8 (IL-8), and MCP-1 (monocyte chemoattractant protein-1) increase insulin resistance and the risk of cardiovascular disease (CVD). There is no previous study that has examined the effect of ketosis and trivalent chromium on IL-6, IL-8, or MCP-1 secretion in any cell type or in human or animal model. The authors examined the hypothesis that ketosis increases and trivalent chromium decreases the levels of cytokines and oxidative stress in diabetes using a U937 monocyte cell culture model. Cells were cultured with control, high glucose (HG), and acetoacetate (AA) in the absence or presence (0.5-10 microM) of CrCl(3), chromium picolinate (Cr-P), or chromium niacinate (Cr-N) at 37 degrees C for 24 h. The data show a significant stimulation of IL-6, IL-8, and MCP-1 secretion and an increase in oxidative stress in cells treated with HG or AA. The effect of HG on cytokine secretion was reduced by Cr-N, and to a lesser extent by CrCl(3) and Cr-P. The effect of HG on oxidative stress was reduced by Cr-N and CrCl 3, but not by Cr-P. Similarly, Cr-N decreased the cytokine secretion in HG + AA-treated cells. Cr-N significantly decreased standard oxidant (H(2)O(2)) induced cytokine secretion, which suggests that reduction of cytokine secretion by Cr-N is in part mediated by its antioxidative effect. In a cell culture model, Cr-N appears to be the most effective form of chromium in inhibiting oxidative stress and proinflammatory cytokine secretion by monocytes. This study suggests that chromium niacinate supplementation may be useful in reducing vascular inflammation and the risk of CVD in diabetes.